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VIEWPOINT

The renin–angiotensin system: An integrated view of
lung disease and coagulopathy in COVID-19 and
therapeutic implications
Betty Diamond

The renin–angiotensin system (RAS) has long been appreciated as a major regulator of blood pressure, but has more recently
been recognized as a mechanism for modulating inﬂammation as well. While there has been concern in COVID-19 patients over
the use of drugs that target this system, the RAS has not been explored fully as a druggable target. The abbreviated
description of the RAS suggests that its dysregulation may be at the center of COVID-19.
Angiotensin II is a major component of the
renin–angiotensin system (RAS). It is produced from angiotensin I by angiotensinconverting enzyme (ACE; Benigni et al.,
2010). Notably, there is a positive feedback
loop in the RAS whereby angiotensin II can
increase levels of ACE (Koka et al., 2008).
Angiotensin II also leads to increased secretion of aldosterone, which causes Na retention and K excretion (Muñoz-Durango
et al, 2016).
There are two major receptors for angiotensin II that are expressed on numerous
cells. When angiotensin II binds to the ﬁrst
of these receptors, called angiotensin receptor 1 (AT1), expressed on ﬁbroblasts,
cardiac myocytes, smooth muscle cells, adrenal cells, macrophages, microglia, hepatocytes, endothelial cells, and more, the
result is vasoconstriction and activation of
NF-κB and release of pro-inﬂammatory cytokines (Benigni et al., 2010; Dandona et al.,
2007; Okamura et al., 1999). When angiotensin II binds AT1 on alveolar epithelial
cells, it induces apoptosis (Wang et al.,
1999). When it engages AT1 on endothelial
cells, it leads to increased expression of tissue factor (TF), a requisite component of the
clotting cascade (Dielis et al., 2005), and to
vascular permeability and extravasation of
neutrophils into tissue (Nabah et al., 2004).

Engagement of the second angiotensin receptor, AT2, also expressed fairly ubiquitously, by angiotensin II leads to vasodilation
and to suppression of inﬂammation (Crowley
and Rudemiller, 2017). Under both acute and
chronic inﬂammatory conditions, the level of
AT1 is increased and the level of AT2 is decreased (Crowley and Rudemiller, 2017; Koka
et al., 2008; Tikellis and Thomas, 2012).
A second ACE, ACE2, exists as a
membrane-bound protease on numerous
cell types (Clarke et al., 2012). ACE2 cleaves
angiotensin II to produce a small peptide,
ang1-7, which binds to a G protein–coupled
receptor Mas to induce an anti-inﬂammatory
and anti-apoptotic program and vasodilation
(Simões e Silva et al., 2013). ACE2 is the cellular receptor for the SARS-CoV-2 virus (Lan
et al., 2020), the causative agent for COVID-19,
and permits viral entry into ACE2-expressing
cells. When the viral spike protein binds ACE2,
however, another protease termed TACE, or
ADAM 17, is activated; this causes ACE2 to be
shed from the cell membrane, leading to decreased degradation of angiotensin II and decreased production of ang1-7 (Shah and Catt,
2006). Interestingly, a high concentration of
aldosterone reduces Mas expression, also impairing this arm of the RAS (Stoll et al., 2019).
So how does this relate to COVID-19? SARSCoV-2 infection can cause a particularly severe

disease in hypertensive and obese individuals
(Kenyon, 2020; Richardson et al., 2020). Hypertensive individuals generally have high
levels of angiotensin and high levels of TF,
leading to the hypercoagulable state that is
seen in hypertension (Dielis et al., 2005). It is
important to note that renin levels are often
low in African Americans, but there is evidence in rodent models that tissue levels of
angiotensin may be high even in the face of
low renin (Williams et al., 2014). Obesity is
associated with high levels of ACE and AT1
(Barton et al., 2000). Both of these comorbidities will, therefore, enhance the
pro-inﬂammatory, pro-apoptotic, procoagulant arms of the RAS.
A model of COVID-19 might be that
SARS-CoV-2 infects lung alveolar epithelial
cells, the source of surfactant, causing a
cytopathic effect. In addition, angiotensin II
binding to alveolar epithelial cells induces
their death through apoptosis. Because
ACE2 is shed when bound by spike protein,
we speculate that ang1-7 is not generated.
With diminished ang1-7 to bind Mas, there
may be no activation of the arm of the RAS
pathway that protects against apoptosis.
First, therefore, we suggest there is a collapse of alveolae with ensuing hypoxia. Because angiotensin II increases vascular
permeability, there may be extravasation of
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Figure 1. The RAS in health and in SARS-CoV-2 infection. Left: In a healthy individual, there is a balance of AT1, AT2, and membrane-bound ACE2 with
production of ang1-7. Aldosterone increases Mas expression, and ang1-7 binds Mas to suppress inﬂammation. Right: In a SARS-CoV-2–infected individual, there
is an imbalanced RAS, with viral spike protein causing ACE2 shedding, diminished production of ang1-7, and high AT1 with low AT2.

neutrophils into alveolae. Moreover, angiotensin II acting on endothelial cells induces
IL-8 leading to neutrophil recruitment
(Nabah et al., 2004). These neutrophils can
release ROS and form neutrophil extracellular traps (Khan et al., 2017). Indeed, neutrophils in the alveolae have been seen in
lung pathology of infected patients (Barnes
et al., 2020). This accumulation of neutrophils, we propose, will lead to netosis and
hypercapnia with inadequate diffusion of
CO2 through the alveolae if our model is
correct. Surfactant, which usually protects
against netosis (Rodriguez et al., 2019), will
be sparse due to the loss of alveolar epithelial cells. This may lead to an impairment in
lung function that appears to be like what is
seen in acute respiratory distress syndrome,
but in SARS-CoV-2 infection, the destruction of lung function may progress through
a different pathway. In acute respiratory
distress syndrome, the loss of lung function
is a consequence of cytokine storm due to
the activation of the innate and adaptive
immune systems. We propose that, in
COVID-19, the lung is destroyed by a combination of the cytopathic effect of the virus
and an imbalanced RAS with too much AT1
and insufﬁcient ACE2 (Fig. 1). This is the
crux of the issue and would explain the
greater disease severity in the elderly as
well as in hypertensive and obese individuals, rather than in young and healthy
individuals. In this model, the key issue is
the loss of ACE2 due to ACE2 engagement of
the spike protein and activation of TACE.
Indeed, ACE2 deﬁciency exacerbates disease
in mouse models of methicillin-resistant
Staphylococcus aureus and two strains of

inﬂuenza (Khan et al., 2017; Yang et al.,
2014; Zou et al., 2014). In patients infected
with H5N1 bird ﬂu, angiotensin II levels rise,
with high levels associated with greater
disease severity. Similarly, in mice infected
with H5N1, angiotensin II levels predict
outcome, and ACE2 deﬁciency leads to
greater mortality (Zou et al., 2014). In mice
infected with H5N9, ACE2 deﬁciency also
leads to more severe disease. Angiotensin,
not cleaved by ACE2, binds the AT1 receptor,
contributing to pathology; an AT1 receptor
inhibitor, losartan, improves disease outcome (Yang et al., 2014). Interestingly, in a
mouse model of Pseudomonas aeruginosa infection, a deﬁciency of ACE2 function leads
to increased neutrophil accumulation in the
lung through an IL-17–dependent pathway
(Sodhi et al., 2019).
The increased TF in endothelial cells
leads to thrombosis, which is present in
numerous hospitalized COVID-19 patients
(Bikdeli et al., 2020; Klok et al., 2020). The
increased aldosterone may be responsible
for the hypokalemia seen in many COVID-19
patients. More speculatively, while the inﬂammatory arm of the RAS produces TNF,
IL-6, and other pro-inﬂammatory cytokines
without producing interferon, ACE cleaves
bradykinin, a known suppressor of interferon, and so might lead to increased interferon in some individuals (Seliga et al.,
2018). Some individuals with a particular
genetic predisposition may produce high
levels of interferon, and these may be the
individuals who develop “COVID toes”
(Landa et al., 2020; Zhang et al., 2020). This
predisposition may include those genes with
risk alleles in systemic lupus erythematosus
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(SLE) that have a propensity for high interferon production (Ghodke-Puranik and
Niewold, 2015). Interestingly, low interferon is seen in many COVID-19 patients and
is more consistent with activation of the
RAS pathway than activation of TLRs
(Hadjadj et al., 2020 Preprint). TLR activation induces interferon; activation of AT1 by
angiotensin II, in contrast, leads to proinﬂammatory cytokines but not interferon
(Meng et al., 2017).
There are implications of this model.
First, COVID-19 patients will have a high
level of angiotensin II, perhaps even African
Americans, and a low level of ang1-7 due to
the diminished activity of ACE2. Second,
those with COVID toes may have risk alleles
in the interferon pathway, similar to some
SLE risk alleles, as similar pathology is seen
in SLE and interferonopathies (Kolivras
et al., 2020). High interferon may lead to
an effective antiviral response but also
have the negative consequence of leading
to interferon-induced microangiopathy
(Massey and Jones, 2020). ACE inhibitors
might be beneﬁcial rather than harmful.
Angiotensin receptor blockers, which preferentially target AT1, might also be useful.
While there was initial concern over the use
of these drugs, as they increase ACE2 expression when used not in the context of
COVID-19 (Vaduganathan et al., 2020), it is
now clear they are not harmful in the context of the virus and may indeed be beneﬁcial (Ghosal et al., 2020 Preprint; Robertson,
2020). Finally, the use of the ang1-7 peptide
to counter the effects of the angiotensin–AT1
interaction might be a novel therapeutic to
pursue.
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